Advisory Services Network’s UroGen Pharma URGN Stock Holding History

Advisory Services Network’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.94K	Buy	+553	New	+$11.1K	﹤0.01%	3563
2025 Q4	–	Sell	-550	Closed	-$11K	–	4124
2025 Q3	$11K	Buy	+550	New	+$9.88K	﹤0.01%	3246

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Advisory Services Network's URGN Position: Q1 2026 in Review

Advisory Services Network opened a new position in UroGen Pharma (URGN) in Q1 2026: 553 shares worth $9.94K. The stake represents ﹤0.01% of the portfolio and ranks #3563 among its holdings. This is a return to the name: Advisory Services Network previously reported a position in URGN as recently as Q3 2025.

Advisory Services Network first reported a position in URGN in Q3 2025 and has held it in 2 quarters since. The position peaked at $11K in Q3 2025. 172 funds tracked by Wall St. Rank hold URGN as of Q1 2026.

Advisory Services Network held 553 shares of UroGen Pharma worth $9.94K as of Q1 2026.
UroGen Pharma was a new Advisory Services Network position in Q1 2026.
UroGen Pharma made up ﹤0.01% of Advisory Services Network's portfolio in Q1 2026, its #3563 holding.
Advisory Services Network first reported a position in UroGen Pharma in Q3 2025 and has held it in 2 quarters since.
Advisory Services Network's UroGen Pharma position peaked at $11K in Q3 2025.
172 funds tracked by Wall St. Rank held UroGen Pharma as of Q1 2026.

Based on Advisory Services Network's 13F filing for Q1 2026, filed 15 May 2026.